News | November 07, 2025
Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
The survey revealed that the proportion of individuals experiencing constant thoughts about food throughout the day declined by 46 percent after starting Wegovy
Cagrilintide represents a novel approach to obesity management
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Subscribe To Our Newsletter & Stay Updated
